US Patent Issued to Crititech on June 17 for "Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer" (Kansas Inventors)

ALEXANDRIA, Va., June 19 -- United States Patent no. 12,329,858, issued on June 17, was assigned to Crititech Inc. (Lawrence, Kan.).

"Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer" was invented by Gere S. Dizerega (Lawrence, Kan.), Michael Baltezor (Lawrence, Kan.), Sam Campbell (Lawrence, Kan.), Charles J. Decedue (Lawrence, Kan.), Matthew McClorey (Lawrence, Kan.) and Holly Maulhardt (Lawrence, Kan.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed are combination therapy methods useful for the therapeutic treatment of cancer by combining local administration of compositions containing antineoplastic particles...